Sharing Our Strength: A Research Study for Bone Marrow/Stem Cell Transplant Survivors

University of North Carolina (UNC)

Status: Completed

Conditions: Acute Leukemia; Acute Lymphocytic Leukemia; Multiple Myeloma; Leukemia; Hematological Cancers; Psychological Distress

Treatments: Behavioral: Writing D (Control noninformative writing); Behavioral: Writing C (Control informative writing); Behavioral: Writing A (Experimental informative writing); Behavioral: Writing B (Experimental noninformative writing)

Study type: Interventional

Funder types: Other

Identifiers

NCT00701844

GCO #06-0391 (2)

RSGPB-07-285-01-CPPB (Other Identifier)

Details and patient eligibility

About

The Sharing Our Strength study is being conducted to help us understand people's experiences with hematopoietic stem cell transplantation and to test a new program designed to help people recover physically and emotionally after transplant.

Full description

This is a study for survivors of hematopoietic stem cell transplantation (also known as bone marrow transplant), which is an intensive medical treatment for cancers such as leukemia, lymphoma, and multiple myeloma as well as other diseases. Because it is a physically and emotionally demanding treatment, many people report having ongoing physical and emotional difficulties after having a transplant. The Sharing Our Strength study is being conducted to help us understand people's transplant experiences and to test a new program designed to help them recover physically and emotionally after transplant. All parts of the study are completed by mail and telephone. Participants will receive compensation for their time.

Enrollment: 315 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be a transplant survivor who is 9 months to 3 years beyond transplant and not currently relapsed. and not currently relapsed
• Be at least 18 years old now (and at least 16 when they had their transplant)
• Speak English
• Have telephone service

Exclusion criteria

• None

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Double Blind

---

315 participants in 4 patient groups, including a placebo group

Experimental Writing Type 1

Experimental group

Treatment:

Behavioral: Writing A (Experimental informative writing)

Experimental Writing type 2

Experimental group

Treatment:

Behavioral: Writing B (Experimental noninformative writing)

Control writing type 1

Active Comparator group

Treatment:

Behavioral: Writing C (Control informative writing)

Control writing type 2

Placebo Comparator group

Treatment:

Behavioral: Writing D (Control noninformative writing)